Pfizer Global Medical Grants – RFP in Non-Alcoholic Steatohepatitis
Academic Unit: inquire with unit
Memorial Deadline: Friday 17th, June 2022
External Deadline: Wednesday 22nd, June 2022
Request for Proposals (RFP)
Addressing Diagnostic Challenges for Non-Alcoholic Steatohepatitis (NASH)
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Geographic Scope: Global
Clinical Area: Non-Alcoholic Steatohepatitis (NASH)
Application Due Date: June 22, 2022
Specific Area of Interest: It is our intent to provide an independent grant(s) to an organization or organizations that will focus on developing educational programs to help inform about the diagnosis of NASH beyond biopsy by applying non-invasive tools for NASH and the use of real-world data to develop predictive models that identify the patients at risk of progressing into advanced stages of liver disease.
Projects that will be considered for Pfizer support will focus on:
- dissemination of information related to current and innovative non-invasive tools in-development to diagnose and monitor NASH
increasing awareness of the added value of real-word evidence to address gaps in patient screening, identification and how they could support of the proper diagnosis of NASH